| Identification | Back Directory | [Name]
RORγt agonist 1 | [CAS]
2377378-89-5 | [Synonyms]
RORγt agonist 1
2-(6-(3-(difluoromethoxy)-5-fluorophenyl)-1-((3-(trifluoromethyl)phenyl)sulfonyl)indolin-2-yl)acetic acid
1H-Indole-2-acetic acid, 6-[3-(difluoromethoxy)-5-fluorophenyl]-2,3-dihydro-1-[[3-(trifluoromethyl)phenyl]sulfonyl]- | [Molecular Formula]
C24H17F6NO5S | [MDL Number]
MFCD32201096 | [MOL File]
2377378-89-5.mol | [Molecular Weight]
545.45 |
| Hazard Information | Back Directory | [Uses]
RORγt agonist 1 (compound 14) is a potent, orally bioavailable RORγt agonist with an EC50 of 20.8?nM. RORγt agonist 1 showes high metabolic stability, improved aqueous solubility and excellent mouse PK profile. RORγt agonist 1 is a potential candidate of RORγt agonist for cancer immunotherapy[1]. | [in vivo]
RORγt agonist 1 shows high metabolic stability (t1/2?=?113?min) in mouse liver microsome and has improved aqueous solubility at pH 7.4[1]. | [References]
[1] Zhu Y, et al. Discovery of aryl-substituted indole and indoline derivatives as RORγt agonists. Eur J Med Chem. 2019 Aug 6;182:111589. DOI:10.1016/j.ejmech.2019.111589 |
|
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|